60 F
New York
Friday, May 7, 2021

Here’s Why Cassava Sciences [NASDAQ: SAVA] Plunged On Friday?

Must read

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Cassava Sciences Inc. [NASDAQ: SAVA] shares plummeted 25.13% during the trading session of Friday. The biotechnology company has announced Friday the pricing of its previously disclosed underwritten public offering.

Cassava Sciences has provided the offer of 9,375,000 shares of its common stock, par value $0.001 per share, at a price to the public of $8.00 per share. It has given the 30-day option of additional 1,406,250 shares of common stock purchases to the underwriters.

Cassava Sciences [NASDAQ: SAVA] shares were trading down 25.13% at $8.37 at the time of writing on Friday. Cassava Sciences [NASDAQ: SAVA] share price went from a low point around $1.21 to briefly over $12.68 in the past 52 weeks. Furthermore, the SAVA market cap has remained high, hitting $204.90 Million at the time of writing.

The company reported that Cantor Fitzgerald & Co. will lead the offering as a book-running manager. H.C. Wainwright & Co. are serving as joint book-running manager for the offering. Maxim Group LLC is serving as a co-manager for the offering.

It has been revealed that the company will receive a gross profit from the offering of approximately $75.0 million. Cassava Sciences would use the profits from the offering to fund a Phase III clinical program of sumifilam. Additionally, Sumifilam is the lead candidate of the company for the treatment of Alzheimer’s disease.

Moreover, the offering will be anticipated to close on or about November 17, 2020, after satisfying the closing conditions.

More articles

Latest article

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...

R1 RCM [NASDAQ: RCM] Announces Acquisition of VisitPay

R1 RCM Inc. disclosed Tuesday that it has decided to purchase VisitPay. The firm has inked an agreement to buy VisitPay for nearly...

Binance Coin Makes History as its Market Cap Reach $100 Billion

The market capitalization of Binance set new records as the exchange token of Binance and the native asset of Binance Smart Chain (BSC) touched...

Precipio [NASDAQ: PRPO] Roll Out Rapid COVID-19 Antibody test on Amazon Platform

Shares of Precipio, Inc. skyrocketed 40.35% during the trading session of Monday. The strong performance of the firm has highlighted the positive sentiments...

TechX Ink Deal to Buy Fiat-to-Crypto Merchant Services Gateway XPort Digital

TechX Technologies Inc disclosed Monday that it has bought fiat-to-crypto merchant services gateway XPort digital. The firm has bought a 100% stake in XPort...

Lockheed [NYSE: LMT] Present F-35 Best and Final Offer to Finnish Government

Lockheed Martin Corporation disclosed that it has presented F-35 best and final offer (BAFO) on April 29, 2021, to the Finnish government. It...

Clene [NASDAQ: CLNN] Gets Two Patent Notice of Allowances

Clene Inc. disclosed that Clene Nanomedicine, Inc. U.S. Patent and Trademark Office has provided Notices of Allowance for two significant patent applications. Clene...